Skip to main content
. Author manuscript; available in PMC: 2009 Jul 2.
Published in final edited form as: J Invest Dermatol. 2008 Jun 12;128(12):2888–2893. doi: 10.1038/jid.2008.162

Table 1.

ORs and 95% CIs for HPV infection according to tumor histology

HPV DNA positivity BCC (n=98) SCC (n=98) OR (95% CI)1
Overall
 No β-types positive 22 (22.4) 16 (16.3) Referent
 Any β-HPV 76 (77.6) 82 (83.7) 1.5 (0.7–3.5)
Previously reported types
 No or other β-types 58 (59.2) 37 (37.8) Referent
 HPV 5, 8, 15, 20, 24, 36, and/or 38 40 (40.8) 61 (62.2) 2.6 (1.4–5.1)
Multiple infection
 No or 1 β-type 49 (50.0) 32 (32.7) Referent
 More than 1 β-type 49 (50.0) 66 (67.3) 2.0 (1.0–3.9)
Phylogenic species
 No β1 HPV 52 (53.1) 35 (35.7) Referent
 Any β1 HPV 46 (46.9) 63 (64.3) 2.0 (1.1–3.6)
  HPV 5 5 (5.1) 6 (6.1)
  HPV 8 4 (4.1) 6 (6.1)
  HPV 12 1 (1.0) 5 (5.1)
  HPV 14 1 (1.0) 4 (4.1)
  HPV 19 0 (0.0) 3 (3.1)
  HPV 20 7 (7.1) 9 (9.2)
  HPV 21 3 (3.1) 6 (6.1)
  HPV 24 9 (9.2) 15 (15.3)
  HPV 25 0 (0.0) 0 (0.0)
  HPV 36 18 (18.4) 20 (20.4)
  HPV 47 5 (5.1) 5 (5.1)
  HPV 93 18 (18.4) 15 (15.3)
 No β2 HPV 42 (42.9) 32 (32.7) Referent
 Any β2 HPV 56 (57.1) 66 (67.3) 1.4 (0.7–2.5)
  HPV 9 18 (18.4) 23 (23.5)
  HPV 15 14 (14.3) 25 (25.5)
  HPV 17 16 (16.3) 24 (24.5)
  HPV 22 2 (2.0) 5 (5.1)
  HPV 23 19 (19.4) 20 (20.4)
  HPV 37 12 (12.2) 12 (12.2)
  HPV 38 10 (10.2) 15 (15.3)
  HPV 80 9 (9.2) 15 (15.3)
 No β3, β4, and/or β5 HPV 69 (70.4) 66 (67.3) Referent
 Any β3, β4, and/or β5 HPV 29 (29.6) 32 (32.7) 1.0 (0.5–2.0)
  HPV 49 0 (0.0) 6 (6.1)
  HPV 75 1 (1.0) 3 (3.1)
  HPV 76 25 (25.5) 21 (21.4)
  HPV 92 2 (2.0) 7 (7.1)
  HPV 96 2 (2.0) 3 (3.1)

CI, confidence interval; BCC, basal cell carcinoma; HPV, human papillomavirus; OR, odds ratio; SCC, squamous cell carcinoma.

1

ORs are adjusted for age, sex, education, smoking, skin sensitivity to sunlight, and lifetime sunburns.